Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Specified Drug-use Survey of Lotriga Granular Capsules: OCEAN3 (Outcome Prevention on Cardiovascular Events by Antihyperlipidemic Therapy With N3-fatty Acid in Japan)

NCT02285166 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02285166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02285166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Specified Drug-use Survey of Lotriga Granular Capsules: OCEAN3 (Outcome Prevention on Cardiovascular Events by Antihyperlipidemic Therapy With N3-fatty Acid in Japan)
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
October 21, 2014
Completion date
July 14, 2020
Enrollment
15,330 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia